Skip to main content
Journal cover image

Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.

Publication ,  Journal Article
Mannelli, P; Douaihy, AB; Akerman, SC; Legedza, A; Fratantonio, J; Zavod, A; Sullivan, MA
Published in: Am J Addict
March 2022

BACKGROUND AND OBJECTIVES: Treatment for individuals receiving medication for opioid use disorder (MOUD) should follow an informed patient-centered approach. To better support patient autonomy in the decision-making process, clinicians should be aware of patient preferences and be prepared to educate and assist patients in transitioning from one MOUD to another, when clinically indicated. This posthoc analysis describes the characteristics of clinical trial participants (NCT02696434) with a history of opioid use disorder (OUD) seeking to transition from buprenorphine (BUP) to extended-release naltrexone (XR-NTX). METHODS: The posthoc analysis included adults with OUD currently receiving BUP (≤8 mg/day) and seeking transition to XR-NTX (N = 101) in a residential setting. Baseline participant characteristics and OUD treatment history were reviewed. All patients completed a screening questionnaire that asked about their reasons for seeking transition to XR-NTX and for choosing BUP. RESULTS: The most common reasons for initiating a transition to XR-NTX were "Seeking to be opioid-free" (63.4%) and "Tired of daily pill taking" (25.7%). Positive predictors of transition included a more extensive BUP treatment history and a history of prescription opioid abuse. Most participants stated they were not aware of XR-NTX as a treatment option when initiating BUP (78.2%). DISCUSSIONS AND CONCLUSIONS: Patients' reasons for seeking XR-NTX transition, more extensive BUP treatment history, and a history of prescription opioid abuse, may positively predict outcomes. SCIENTIFIC SIGNIFICANCE: These findings may assist clinicians in optimizing outcomes of the BUP to XR-NTX transition and supporting patients to make better informed MOUD decisions.

Duke Scholars

Published In

Am J Addict

DOI

EISSN

1521-0391

Publication Date

March 2022

Volume

31

Issue

2

Start / End Page

142 / 147

Location

England

Related Subject Headings

  • Substance Abuse
  • Opioid-Related Disorders
  • Narcotic Antagonists
  • Naltrexone
  • Injections, Intramuscular
  • Humans
  • Delayed-Action Preparations
  • Buprenorphine
  • Adult
  • 5203 Clinical and health psychology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mannelli, P., Douaihy, A. B., Akerman, S. C., Legedza, A., Fratantonio, J., Zavod, A., & Sullivan, M. A. (2022). Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting. Am J Addict, 31(2), 142–147. https://doi.org/10.1111/ajad.13264
Mannelli, Paolo, Antoine B. Douaihy, Sarah C. Akerman, Anna Legedza, James Fratantonio, Abigail Zavod, and Maria A. Sullivan. “Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting.Am J Addict 31, no. 2 (March 2022): 142–47. https://doi.org/10.1111/ajad.13264.
Mannelli P, Douaihy AB, Akerman SC, Legedza A, Fratantonio J, Zavod A, Sullivan MA. Characteristics and treatment preferences of individuals with opioid use disorder seeking to transition from buprenorphine to extended-release naltrexone in a residential setting. Am J Addict. 2022 Mar;31(2):142–147.
Journal cover image

Published In

Am J Addict

DOI

EISSN

1521-0391

Publication Date

March 2022

Volume

31

Issue

2

Start / End Page

142 / 147

Location

England

Related Subject Headings

  • Substance Abuse
  • Opioid-Related Disorders
  • Narcotic Antagonists
  • Naltrexone
  • Injections, Intramuscular
  • Humans
  • Delayed-Action Preparations
  • Buprenorphine
  • Adult
  • 5203 Clinical and health psychology